You are here

  • Home
  • Archive
  • Volume 7, Issue 1
  • First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy

Article info

Article menu

Download PDFPDF

XML
Commentary
First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy

Authors

  • Yixin Zhou State Key Laboratory of Oncology in South China Guangzhou China Collaborative Innovation Center for Cancer Medicine Guangzhou China Department of VIP regionSun Yat-sen University Cancer Center Guangzhou China PubMed articlesGoogle scholar articles
  • Zuan Lin State Key Laboratory of Oncology in South China Guangzhou China Collaborative Innovation Center for Cancer Medicine Guangzhou China Department of Clinical ResearchSun Yat-sen University Cancer Center Guangzhou China PubMed articlesGoogle scholar articles
  • Xuanye Zhang State Key Laboratory of Oncology in South China Guangzhou China Collaborative Innovation Center for Cancer Medicine Guangzhou China Department of Medical OncologySun Yat-sen University Cancer Center 651 Dongfeng East Road 510060 Guangzhou China PubMed articlesGoogle scholar articles
  • Chen Chen State Key Laboratory of Oncology in South China Guangzhou China Collaborative Innovation Center for Cancer Medicine Guangzhou China Department of RadiotherapySun Yat-sen University Cancer Center Guangzhou China PubMed articlesGoogle scholar articles
  • Hongyun Zhao State Key Laboratory of Oncology in South China Guangzhou China Collaborative Innovation Center for Cancer Medicine Guangzhou China Department of Clinical ResearchSun Yat-sen University Cancer Center Guangzhou China PubMed articlesGoogle scholar articles
  • Shaodong Hong State Key Laboratory of Oncology in South China Guangzhou China Collaborative Innovation Center for Cancer Medicine Guangzhou China Department of Medical OncologySun Yat-sen University Cancer Center 651 Dongfeng East Road 510060 Guangzhou China PubMed articlesGoogle scholar articles
  • Li Zhang State Key Laboratory of Oncology in South China Guangzhou China Collaborative Innovation Center for Cancer Medicine Guangzhou China Department of Medical OncologySun Yat-sen University Cancer Center 651 Dongfeng East Road 510060 Guangzhou China PubMed articlesGoogle scholar articles

Citation

Zhou Y, Lin Z, Zhang X, et al
First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy
Journal for ImmunoTherapy of Cancer 2019;7:120. doi: 10.1186/s40425-019-0600-6
Online issue publication 
January 08, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© The Author(s). Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.